Sign In
Buy ELEV
$0.365
+0 (+0%)
At Close: Oct 22, 2025
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
07:30am, Thursday, 12'th Dec 2024
-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload – -- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's
-- Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric or gastroesophageal junction (GEJ
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference
07:30am, Tuesday, 26'th Nov 2024
BOSTON , Nov. 26, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
07:30am, Wednesday, 06'th Nov 2024
-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile
What Makes Elevation Oncology (ELEV) a New Strong Buy Stock
01:05pm, Thursday, 10'th Oct 2024
Elevation Oncology (ELEV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Empery Asset Management's Strategic Acquisition in Elevation Oncology
12:02pm, Wednesday, 09'th Oct 2024
On September 30, 2024, Empery Asset Management, LP (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 4,000,000 shares of Elevation Oncology Inc (ELEV, Financial)
BOSTON , Sept. 23, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
07:30am, Tuesday, 03'rd Sep 2024
BOSTON , Sept. 3, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients
Undercovered Dozen: Elevation Oncology, Ivanhoe Mines, Union Pacific, Golub Capital +
01:45pm, Friday, 09'th Aug 2024
We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. A take on Easterly Government Properties suggests they offer reliable income similar to Treasury bonds with
Why Is Penny Stock Elevation Oncology Trading Lower On Tuesday?
12:36pm, Tuesday, 06'th Aug 2024
The stock of Elevation Oncology Inc. ELEV is trading lower on Tuesday after the company reported initial data from the dose escalation portion of the ongoing Phase 1 trial of EO-3021 in patients with
Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements
07:10am, Tuesday, 06'th Aug 2024
-- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety pro
-- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer -- -- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
07:30am, Thursday, 27'th Jun 2024
-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- -- Expect to initiate dosing in combination por
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
07:30am, Tuesday, 07'th May 2024
BOSTON , May 7, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients ac
Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling
01:16pm, Friday, 03'rd May 2024
Results from the phase 1 study, using EO-3021 for the treatment of CLDN 18.2 expressing solid tumors, expected mid-Q3 of 2024; Additional data expected 1st half of 2025. HER3-ADC is another ADC being
